Amgen, Inc. entered 2021 with two new high-profile potential additions to its commercial portfolio – sotorasib for non-small cell lung cancer patients with KRAS G12C mutations and tezepelumab for severe asthma. But while Amgen executive vice presidents David Reese and Murdo Gordon are looking forward to bringing these therapies to market in the next year or so, COVID-19 impacts on sales and competitive pressures remain near-term headwinds to the company’s growth.
Scrip spoke with Reese, EVP of research and development, and Gordon, EVP of global commercial operations, about pivotal data, filing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?